Engineered cleavage half-domains

• US 7,914,796 B2
• Filed: 07/02/2008
• Issued: 03/29/2011
• Est. Priority Date: 05/25/2006
• Status: Active Grant

• Current Assignee: Sangamo Therapeutics, Inc.
• Original Assignee: Sangamo Biosciences, Inc.
• Inventors: Cost, Gregory J., Miller, Jeffrey C., Holmes, Michael C.
• Primary Examiner(s): CHEN, SHIN LIN
• Application Number:
  US12/217,185
• Publication Number:
  US 20090311787A1
• Time in Patent Office: 1,000 Days
• Field of Search: 424/192.1, 530/350, 536/23.1, 435/455, 435/463
• US Class Current: 424/192.1
• CPC Class Codes: C12N 9/22 Ribonucleases RNAses, DNAses catalytic nucleic acids C12N15/113

Abstract

Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising these polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

Claims

1. An in vitro method for cleaving DNA in a cell, the method comprising:

expressing first, second, third and fourth fusion proteins in the cell, each of the fusion proteins comprising;

(i) a zinc finger DNA-binding domain that binds to a target site in the DNA, and

(ii) an engineered FokI cleavage half-domain;

further wherein;

(a) in the engineered FokI cleavage half-domain of the first fusion protein the glutamine (Q) residue at position 486 of a wild-type FokI cleavage half-domain is replaced with a glutamic acid (E) residue Q486E) or;

(b) in the engineered FokI cleavage half-domain of the second fusion protein the glutamic acid (E) residue at position 490 of the wild-type FokI cleavage half-domain is replaced with a lysine (K) residue and the isoleucine (I) residue at position 538 of the wild-type FokI cleavage half-domain is replaced with a lysine (K) residue (E490K;

I538K);

(c) in the engineered FokI cleavage half-domain of the third fusion protein the arginine (R) residue at position 487 of the wild-type FokI cleavage half-domain is replaced with an aspartic acid (D) residue (R487D);

(c) in the engineered FokI cleavage half-domain of the fourth fusion protein the aspartic acid (D) residue at position 483 of the wild-type FokI cleavage half-domain is replaced with an arginine (R) residue (D483R);

(d) the first and second fusion proteins bind to first and second target sites respectively, wherein a first cleavage site lies between the first and second target sites, and

(c) the third and fourth fusion proteins bind to third and fourth target sites respectively, wherein a second cleavage site lies between the third and fourth target sites;

such that the first and second fusion proteins cleave the DNA at the first cleavage site, the third and fourth fusion proteins cleave the DNA at the second cleavage site.

2. The method of claim 1, wherein the DNA is in cellular chromatin.

3. The method of deleting sequences in cellular DNA, the method comprising,

cleaving cellular DNA according to the method of claim 1, the DNA ends are rejoined such that sequences between the first and second cleavage sites are deleted.

4. The method of claim 3, wherein the first and second cleavage sites are on the same chromosome.

5. The method of claim 1, wherein the cell is a eukaryotic cell.

6. The method of claim 5, wherein the cell is a mammalian cell.

7. The method of claim 6, wherein the cell is a human cell.

8. The method of claim 5, wherein the cell is a plant cell.

9. A method for targeted replacement of a genomic sequence, the method comprising:

(a) cleaving a genomic DNA sequence in an isolated cell according to the method of claim 1; and

(b) contacting the cell with a donor polynucleotide, wherein the donor polynucleotide comprises;

(i) sequences homologous to genomic sequences flanking the first and second cleavage sites; and

(ii) an exogenous polynucleotide;

whereby genomic sequences between the first and second cleavage sites are replaced by the exogenous polynucleotide.

10. The method of claim 9, wherein the exogenous polynucleotide comprises a sequence that is homologous but non-identical sequence to the genomic sequence between the first and second cleavage sites.

11. The method of claim 10, wherein the homologous but non-identical sequence comprises a deletion with respect to the genomic sequences.

12. The method of claim 10, wherein the homologous but non-identical sequence comprises an insertion with respect to the genomic sequences.

13. The method of claim 9, wherein the exogenous polynucleotide comprises a sequence that is non-homologous to genomic sequences between the first and second cleavage sites.

14. The method of claim 9, wherein the cell is arrested in the G2 phase of the cell cycle.

15. The method of claim 9, wherein the cell is a eukaryotic cell.

16. The method of claim 15, wherein the cell is a mammalian cell.

17. The method of claim 16, wherein the cell is a human cell.

18. The method of claim 15, wherein the cell is a plant cell.

19. The method of claim 1, wherein the isoleucine residue (I) of position 499 of the engineered FokI cleavage half-domain of the first fusion protein is replaced with a leucine (L) residue (Q486E:

1499L).